Who will pay the price for inaction on superbugs?

While the UK government has been applauded for its efforts in raising awareness about antimicrobial resistance, its efforts to convince pharma to invest in new antibiotics have so far been

As R&D shrinks, UK trials new payment scheme for antibiotics

FDA rejects Nabriva's antibiotic over manufacturing concerns

The FDA has rejected a proposed antibiotic from the Irish biotech Nabriva Therapeutics, citing concerns about manufacturing standards.

NICE assessments could reform in new superbug plan

The UK government has published a new five year plan aimed at tackling antimicrobial resistance (AMR), including a new NHS reimbursement scheme backed by NICE to encourage pharma to develop

Genentech develop Antibiotic with potential to lead to new c...

Superbugs & Superdrugs 2019